Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study

BACKGROUND: Bruton tyrosine kinase (BTK) inhibition targets B‐cell and other non‐T‐cell immune cells implicated in the pathophysiology of pemphigus, an autoimmune disease driven by anti‐desmoglein autoantibodies. Rilzabrutinib is a new reversible, covalent BTK inhibitor demonstrating preclinical eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Murrell, D.F., Patsatsi, A., Stavropoulos, P., Baum, S., Zeeli, T., Kern, J.S., Roussaki‐Schulze, A.‐V., Sinclair, R., Bassukas, I.D., Thomas, D., Neale, A., Arora, P., Caux, F., Werth, V.P., Gourlay, S.G., Joly, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518737/
https://www.ncbi.nlm.nih.gov/pubmed/33942286
http://dx.doi.org/10.1111/bjd.20431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518737/
https://www.ncbi.nlm.nih.gov/pubmed/33942286
http://dx.doi.org/10.1111/bjd.20431

Ejemplares similares